Especially, alectinib was found to decrease the risk of ALK-positive NSCLC progression (HR, 0.70; 95% CI, 0.61–0.80) compared with crizotinib in the network meta-analysis [30]. This evidence concerns the gene ALK and non-small cell lung carcinoma.